Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Joseph Drabick, Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier:
NCT01124734
First received: March 4, 2010
Last updated: September 12, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)